Exceptional Prognostic Testing for Prostate Cancer

Veracyte is dedicated to the continued pursuit of evidence for our genomic tests. Decipher® Prostate is the most validated gene expression test for prostate cancer, delivering actionable insights for physicians and their patients to make informed, personalized treatment decisions across the spectrum of localized prostate cancer.

Decipher Urologic Cancers website
  • Screening
  • Diagnosis
  • Prognosis/​treatment selection
  • Recurrence monitoring

Decipher Prostate

IMPROVING CARE FOR PROSTATE CANCER

Decipher Prostate clarifies treatment planning

An older Black couple dancing.

Veracyte’s Decipher Prostate Genomic Classifier helps physicians and their patients with prostate cancer determine the best treatment plan. The 22-gene test was developed using RNA whole-transcriptome analysis and machine learning,1 which provides a comprehensive approach to evaluating a tumor’s molecular underpinnings. The test is performed on tissue samples obtained during biopsy or surgical removal of the prostate.

The Decipher Prostate test is used to determine how likely the patient’s cancer is to metastasize within the next five years. Armed with this information, the physician may recommend less intensive treatment or earlier, more intensive treatment.2-16 The Decipher Prostate test is designed to give physicians and their patients clarity and confidence in developing a personalized treatment plan.

An older Black couple dancing.

WHEN THE TEST IS USED

Assess risk after prostate cancer diagnosis or surgery to remove the prostate

The Decipher Prostate test helps match treatment timing and intensity with the tumor’s aggressiveness for patients with prostate cancer. Patients with low risk Decipher scores may undergo less intense treatment, while those with high risk Decipher scores may benefit from treatment intensification.2-16

Decipher Prostate logo

LOW RISK

Monitor/less-aggressive treatment (per guidelines)

HIGH RISK

Treatment intensification (per guidelines)

Clinical data for Decipher Prostate

The Decipher Prostate Genomic Classifier is the most validated gene expression test available for use in prostate cancer. Its performance has been demonstrated in more than 75 peer-reviewed published studies comprising nearly 110,000 patients. Decipher Prostate is the only gene expression test with Level 1 evidence for validation in the National Comprehensive Cancer Network’s Clinical Practice Guidelines in Oncology (NCCN Guidelines®).7

>75

studies have been published validating the performance of the Decipher Prostate test.17

~100K

patients were included in validation studies for the Decipher Prostate test.17

FEATURED PUBLICATIONS

In JAMA Oncology: “Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer: An Ancillary Study of the NRG/RTOG 9601 Randomized Clinical Trial”

JAMA Oncology article

In IJROBP: “Genomic Classifier Performance in Intermediate-Risk Prostate Cancer: Results From NRG Oncology/RTOG 0126 Randomized Phase 3 Trial”

IJROBP article
All clinical data

Serving patients across the US

The Decipher Prostate Genomic Classifier is available to patients and their physicians in the US. All testing is performed in Veracyte’s centralized labs. The test is covered by Medicare and private insurers that collectively cover over 195,000 patients.

Veracyte is developing the Decipher Prostate test so it can be performed in laboratories in Europe and elsewhere outside of the US. This is intended to help make the test accessible to patients all over the world.

Featured events

Learn more about Decipher Prostate by meeting with us at upcoming events.

View all events
An older Black man holds medical information, which he reviews with a physician who is a woman with light skin.
A physician holds a clipboard and a patient gestures towards it.

Learn about the Decipher Prostate Cancer test

Decipher Urologic Cancers website

References

  1. Erho N, et al. PLoS ONE. 2013.

  2. Vince Jr RA, et al. Prostate Cancer Prostatic Dis. 2021.

  3. Kim HL, et al. Prostate Cancer Prostatic Dis. 2019.

  4. Herlemann A, et al. Prostate Cancer Prostatic Dis. 2020.

  5. Berlin A, et al. Int J Radiat Oncol Biol Phys. 2019.

  6. Spratt DE, et al. J Clin Oncol. 2018. 18.

  7. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer V.1.2023. © National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed [June 20, 2023]. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. NCCN = National Comprehensive Cancer Network® (NCCN®).

  8. Spratt DE, et al. J Clin Oncol. 2022.

  9. Nguyen PL, et al. Prostate Cancer Prostatic Dis. 2017.

  10. Nguyen PL. et al. Int J Radiat Oncol Biol Phys. 2023.

  11. Den RB, et al. J Clin Oncol. 2015. .

  12. Ross AE, et al. Prostate Cancer Prostatic Dis. 2016

  13. Marascio J, et al. Prostate Cancer Prostatic Dis. 2019

  14. Feng FY, et al. JAMA Oncol. 2021.

  15. Spratt DE, et al. Eur Urol. 2018.

  16. Dal Pra A, et al. Ann Oncol. 2022

  17. Decipher Prostate publications

The Decipher Prostate Genomic Classifier is available in the US as part of Veracyte’s CLIA-validated laboratory developed test (LDT) service. This test has not been cleared or approved by the FDA.

This website contains information on products that are targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for you accessing such information that may not comply with any legal process, regulation, registration or usage in the country of your origin.